1,721,000 research outputs found
Improvement of pathologic gambling symptoms after administration of sertraline: a case report
No full text
Anatomical and functional correlates in major depressive disorder: the contribution of neuroimaging studies.
No full textSeveral studies suggested the neural networks modulating aspects of emotional behaviour to be implicated in the pathophysiology of mood disorders. These networks involve the medial prefrontal cortex (MPFC) and closely related areas in the medial and caudolateral orbital cortex (medial prefrontal network), amygdala, hippocampus, and ventromedial parts of the basal ganglia, where alterations in grey matter volume and neurophysiological activity are found in cases with recurrent depressive episodes. Such findings hold major implications for models of the neurocircuits that underlie depression. In particular, evidence from lesion analysis studies suggests that MPFC and related limbic and striato-pallido-thalamic structures organize emotional expression. The aim of this paper is to review the contribution of the most relevant studies with single photon emission tomography (SPECT), positron emission tomography (PET) and magnetic resonance imaging (MRI) to the understanding of pathophysiology of major depressive disorder (MDD), with particular focus on the reversibility of functional correlates with treatment
Treatment choice and psychometric characteristics: differences between patients who choose bariatric surgical treatment and those who do not.
No full textBACKGROUND:
Among the treatment options offered to patients with severe obesity are surgery and psychotherapy plus dieting. The treatment choice may reflect differences in the psychology of these patients. The objective was to assess the psychopathological differences between patients with obesity who choose surgery and those who choose non-surgical treatment to lose weight.
METHODS:
100 patients with obesity (50 in the non-surgical group [NS]; and 50 in the surgical group [S]; 41 women and 9 men in each group) completed the MMPI-2 and the EDI-2; for the latter, data from 21 S and 24 NS women were available. Comparisons were carried out through analysis of variance.
RESULTS:
The NS group scored higher on the Pa (paranoia) and Pt (psychasthenia) scales of the MMPI-2 compared to the S group. No differences were found on the EDI-2; however, both groups scored higher on the drive-for-thinness and body-dissatisfaction scales, and the NS group scored higher on the bulimia and ineffectiveness scales.
CONCLUSION:
The MMPI-2 was able to distinguish between the NS and S groups, while the EDI-2 found significant eating-related psychopathology in both
A case of social phobia and avoidant personality disorder with erectile dysfunction successfully treated with venlafaxine and add-on reboxetine.
No full textA 25-year-old man with DSM-IV-TR Axis I social phobia and Axis II avoidant personality disorder and erectile dysfunction, presenting with depression, anxiety and insomnia, responded partially to extended release oral venlafaxine (75 mg/die for 6 weeks), but developed side effects and worsening symptoms when dose was increased to 150 mg/die; he responded to a combination of 75 mg/die venlafaxine and 4 mg/die reboxetine and improved on most of his symptoms
Vortioxetine vs. other antidepressants in patients with major depressive episode with or without substance use disorder
No full textAbstract: Background: Major Depressive Episodes (MDEs) may characterise many psychiatric di- sorders. Its pharmacotherapy is laid with unmet needs, rendering the testing of new drugs neces- sary.
Objective: To compare the effects of vortioxetine with those of other antidepressants (OADs) in a 1-year naturalistic setting.
Methods: We included 126 adult patients with anMDE in the course of major depressive (MDD), bipolar (BD), or schizophrenia spectrum disorders (SSOPDs), with or without substance use disor- der (SUD), who received 5-20 mg/day oral vortioxetine, and compared them with 100 patients re- ceiving OADs at baseline and after 1, 3, 8, and 12 months on their scores on the MADRS, the CGI- S, the 24-item BPRS, the YMRS, the Hamilton Anxiety Rating Scale, a Visual Analogue Scale for craving, the Columbia-Suicide Severity Rating Scale, and the WHOQOL-BREF.
Results: Patients on vortioxetine improved similarly to those on OADs on all measures, indepen- dently from having or not a comorbid SUD. However, they improved with time better than their OADcounterparts if affected by BD or SSOPDs, but not MDD, on the CGI-S, BPRS depression, anxiety, and manic symptoms. SUD hampered the response of anxiety to treatment. Men improved on depression with time better than women.
Conclusion: MDEs responded to vortioxetine similarly to OADs by improving in depression, gen- eral psychopathology, anxiety, suicidal thinking, and quality-of-life, independently from SUD co- morbidity. MDEs of patients with BD or SSOPDs on vortioxetine responded better than that of pa- tients on OADs. Clinical Trial Registration No. 17354N
- …
